Two Directors at Eli Lilly & Co bought/sold 1,290 shares at between 0.000USD and 749.240USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
Moody's Ratings (Moody's) assigned a Baa2 rating to the new senior unsecured notes offering of Biogen Inc. ("Biogen"). There are no changes to Biogen's existing ratings including the Baa2 senior unsecured notes ratings. The outlook is stable. Proceeds from the offering will be used to refinance ex...
Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.